JP2004517049A - チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 - Google Patents

チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 Download PDF

Info

Publication number
JP2004517049A
JP2004517049A JP2002525102A JP2002525102A JP2004517049A JP 2004517049 A JP2004517049 A JP 2004517049A JP 2002525102 A JP2002525102 A JP 2002525102A JP 2002525102 A JP2002525102 A JP 2002525102A JP 2004517049 A JP2004517049 A JP 2004517049A
Authority
JP
Japan
Prior art keywords
aliphatic
het
aryl
compound
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002525102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517049A5 (enExample
Inventor
コイパー，リー，フレデリック
ラッキー，ケアレン，エリザベス
ウッド，サード，エドガー，レイモンド
ディッカーソン，スコット，ハワード
ハンター，ロバート，エヌ．
ルツィオ，マイケル，ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2004517049A publication Critical patent/JP2004517049A/ja
Publication of JP2004517049A5 publication Critical patent/JP2004517049A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002525102A 2000-09-01 2001-08-23 チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 Pending JP2004517049A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23005000P 2000-09-01 2000-09-01
PCT/US2001/026423 WO2002020479A1 (en) 2000-09-01 2001-08-23 Substituted oxindole derivatives as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2004517049A true JP2004517049A (ja) 2004-06-10
JP2004517049A5 JP2004517049A5 (enExample) 2005-04-07

Family

ID=22863755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002525102A Pending JP2004517049A (ja) 2000-09-01 2001-08-23 チロシンキナーゼ阻害剤としての置換オキシインドール誘導体

Country Status (5)

Country Link
US (2) US7071217B2 (enExample)
EP (1) EP1339680A1 (enExample)
JP (1) JP2004517049A (enExample)
AU (1) AU2001288374A1 (enExample)
WO (1) WO2002020479A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508336A (ja) * 2001-09-27 2005-03-31 アラーガン、インコーポレイテッド キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類
JP2010530401A (ja) * 2007-06-21 2010-09-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インドリン−２−オンおよびアザ−インドリン−２−オン

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071217B2 (en) * 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
JP4584713B2 (ja) 2002-10-08 2010-11-24 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
PL379983A1 (pl) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
CA2549869C (en) 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
ATE486859T1 (de) * 2004-10-25 2010-11-15 Ligand Pharm Inc Verbindungen modulierende thrombopoietinaktivität und verfahren
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
AU2006248780B2 (en) 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
CN101426774B (zh) 2006-04-19 2012-04-25 安斯泰来制药有限公司 唑类甲酰胺衍生物
MX2009000456A (es) 2006-07-13 2009-01-27 Janssen Pharmaceutica Nv Derivados de quinazolina mtki.
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
WO2009016132A1 (en) 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
EP2292089A1 (en) 2008-01-11 2011-03-09 Astellas Pharma Inc. Model animal having both pain in testis or testis-related discomfort actions and frequent urination
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
EP4514998A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
US20240310383A1 (en) 2023-03-17 2024-09-19 Regeneron Pharmaceuticals, Inc. Proteomic Risk Score For Osteoarthritis (OA)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6269086B1 (en) 1998-02-27 2001-07-31 Legerity, Inc. Arrangement and method for selectable time/frequency division multiplex communication
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6498176B1 (en) 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
US7071217B2 (en) * 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2005508337A (ja) 2001-09-27 2005-03-31 スミスクライン ビーチャム コーポレーション 化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508336A (ja) * 2001-09-27 2005-03-31 アラーガン、インコーポレイテッド キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類
JP2010116411A (ja) * 2001-09-27 2010-05-27 Allergan Inc キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類
JP2010530401A (ja) * 2007-06-21 2010-09-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インドリン−２−オンおよびアザ−インドリン−２−オン

Also Published As

Publication number Publication date
WO2002020479A1 (en) 2002-03-14
AU2001288374A1 (en) 2002-03-22
US7338966B2 (en) 2008-03-04
US20030195234A1 (en) 2003-10-16
US7071217B2 (en) 2006-07-04
US20050228025A1 (en) 2005-10-13
EP1339680A1 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
US7071217B2 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
US6268391B1 (en) Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases
US6541503B2 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
EP1430053B1 (en) AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
US6964977B2 (en) Oxindole derivatives
ES2199156T3 (es) Derivados de aza-oxindol sustituidos.
US6624171B1 (en) Substituted aza-oxindole derivatives
WO2019062329A1 (zh) 4,6,7-三取代1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途
JP5296790B2 (ja) 抗増殖性疾患剤としてのピラゾロ［３，４−ｄ］−ピリミジン誘導体
JP7537002B2 (ja) Ｃｄｋ９阻害剤およびその使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120327